Five Prime Therapeutics reported $265.1M in Equity Capital and Reserves for its fourth fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Amgen AMGN:US $ 8217M 30M
Astrazeneca AZN:US $ 39744M 24068M
AstraZeneca AZN:LN 39744M 24068M
Bristol Myers Squibb BMY:US $ 37213M 405M
Clovis Oncology CLVS:US $ -225.46M 18.48M
Cytokinetics CYTK:US $ 249.02M 232.53M
Daiichi Sankyo 4568:JP Y 1312228M 32130M
Eli Lilly And LLY:US $ 7757M 1312.6M
GlaxoSmithKline GSK:LN 15426M 49M
Glaxosmithkline GSK:US $ 15426M 49M
Halozyme Therapeutics HALO:US $ 281.67M 161.93M
Immunogen IMGN:US $ 77.09M 8.63M
Ironwood Pharmaceuticals IRWD:US $ 579.94M 68.18M
Karyopharm Therapeutics KPTI:US $ -125977000 42.84M
Macrogenics MGNX:US $ 291.44M 27.61M
Novartis NVS:US $ 56771M 2729M
Novartis NOVN:VX SF 56771M 2729M
Sangamo Biosciences SGMO:US $ 406.02M 39.44M
Xencor XNCR:US $ 618.86M 28.08M
Ziopharm Oncology ZIOP:US $ 68.71M 19.57M